EA200601985A1 - Новые производные индазола и индолона и их применение в качестве фармацевтических средств - Google Patents

Новые производные индазола и индолона и их применение в качестве фармацевтических средств

Info

Publication number
EA200601985A1
EA200601985A1 EA200601985A EA200601985A EA200601985A1 EA 200601985 A1 EA200601985 A1 EA 200601985A1 EA 200601985 A EA200601985 A EA 200601985A EA 200601985 A EA200601985 A EA 200601985A EA 200601985 A1 EA200601985 A1 EA 200601985A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sexual
disorders
compounds
sexual dysfunction
dysfunction
Prior art date
Application number
EA200601985A
Other languages
English (en)
Inventor
Шарлотт Мойра Норфор Аллертон
Дэвид Хепворт
Дункан Чарльз Миллер
Original Assignee
Пфайзер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411810A external-priority patent/GB0411810D0/en
Priority claimed from GB0415455A external-priority patent/GB0415455D0/en
Application filed by Пфайзер Лимитед filed Critical Пфайзер Лимитед
Publication of EA200601985A1 publication Critical patent/EA200601985A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение относится к соединениям формулы (I), которые являются классом агонистов допамина, более конкретно классом агонистов, которые являются селективными преимущественно для D3 свыше D2. Эти соединения применимы для лечения и/или профилактики сексуальной дисфункции, например женской сексуальной дисфункции (FSD), в частности, нарушения сексуального возбуждения у женщин (FSAD), снижения сексуального влечения (HSDD, недостаточности интереса к сексу), женского оргазмического расстройства (FOD; неспособности достигать оргазма), и мужской сексуальной дисфункции, в частности, мужской эректильной дисфункции (MED). Упоминаемая здесь мужская сексуальная дисфункция, как подразумевается, включает расстройства семяизвержения, такие как преждевременное семяизвержение, аноргазмия (неспособность достигать оргазма), или нарушения влечения, такие как снижение сексуального влечения (HSDD, недостаточность интереса к сексу). Эти соединения применимы также для лечения нейропсихиатрических расстройств и нейродегенеративных расстройств.
EA200601985A 2004-05-26 2005-05-17 Новые производные индазола и индолона и их применение в качестве фармацевтических средств EA200601985A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411810A GB0411810D0 (en) 2004-05-26 2004-05-26 New indazole and indolone derivatives and their use as pharmaceuticals
GB0415455A GB0415455D0 (en) 2004-07-09 2004-07-09 New indazole and indolone derivatives and their use as pharmaceuticals
PCT/IB2005/001513 WO2005116027A2 (en) 2004-05-26 2005-05-17 Indazole and indolone derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
EA200601985A1 true EA200601985A1 (ru) 2007-04-27

Family

ID=35219654

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601985A EA200601985A1 (ru) 2004-05-26 2005-05-17 Новые производные индазола и индолона и их применение в качестве фармацевтических средств

Country Status (25)

Country Link
EP (1) EP1753763B1 (ru)
JP (2) JP4093588B2 (ru)
AP (1) AP2006003823A0 (ru)
AR (1) AR049191A1 (ru)
AT (1) ATE404560T1 (ru)
AU (1) AU2005247696A1 (ru)
BR (1) BRPI0511533A (ru)
CA (1) CA2568050A1 (ru)
CR (1) CR8772A (ru)
DE (1) DE602005008954D1 (ru)
EA (1) EA200601985A1 (ru)
EC (1) ECSP067024A (ru)
ES (1) ES2308492T3 (ru)
GT (1) GT200500118A (ru)
IL (1) IL179365A0 (ru)
MA (1) MA28606B1 (ru)
MX (1) MXPA06013759A (ru)
NL (1) NL1029128C2 (ru)
NO (1) NO20065328L (ru)
PA (1) PA8635001A1 (ru)
PE (1) PE20060289A1 (ru)
SV (1) SV2005002128A (ru)
TW (1) TW200607500A (ru)
UY (1) UY28918A1 (ru)
WO (1) WO2005116027A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590086B2 (en) 2014-11-03 2020-03-17 Iomet Pharma Ltd. Pharmaceutical compound

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2860B1 (en) 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
EP2667875A4 (en) * 2011-01-24 2014-07-30 Inceptum Res & Therapeutics Inc COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
AU6246198A (en) * 1997-02-18 1998-09-08 American Home Products Corporation 4-aminoethoxyindazole derivatives
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
PL377480A1 (pl) * 2002-12-10 2006-02-06 Pfizer Inc. Pochodne morfoliny do stosowania jako agoniści dopaminy w leczeniu między innymi dysfunkcji seksualnej

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590086B2 (en) 2014-11-03 2020-03-17 Iomet Pharma Ltd. Pharmaceutical compound
RU2719446C2 (ru) * 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
US11130738B2 (en) 2014-11-03 2021-09-28 Iomet Pharma Ltd. Pharmaceutical compound

Also Published As

Publication number Publication date
UY28918A1 (es) 2005-12-30
GT200500118A (es) 2006-01-10
WO2005116027A2 (en) 2005-12-08
EP1753763A2 (en) 2007-02-21
PE20060289A1 (es) 2006-04-22
SV2005002128A (es) 2005-12-13
DE602005008954D1 (de) 2008-09-25
PA8635001A1 (es) 2006-05-16
CA2568050A1 (en) 2005-12-08
TW200607500A (en) 2006-03-01
EP1753763B1 (en) 2008-08-13
IL179365A0 (en) 2007-03-08
AR049191A1 (es) 2006-07-05
ATE404560T1 (de) 2008-08-15
WO2005116027A3 (en) 2006-04-13
AU2005247696A1 (en) 2005-12-08
JP4093588B2 (ja) 2008-06-04
NL1029128A1 (nl) 2005-11-30
NO20065328L (no) 2006-12-18
JP2008074874A (ja) 2008-04-03
ECSP067024A (es) 2006-12-29
CR8772A (es) 2006-12-13
MA28606B1 (fr) 2007-05-02
NL1029128C2 (nl) 2006-06-14
MXPA06013759A (es) 2007-02-08
AP2006003823A0 (en) 2006-12-31
JP2008500329A (ja) 2008-01-10
BRPI0511533A (pt) 2008-01-02
ES2308492T3 (es) 2008-12-01

Similar Documents

Publication Publication Date Title
TW200609216A (en) New aminopyridine derivatives and their use as pharmaceuticals
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
EA201270012A1 (ru) Сублингвальный апоморфин
ATE301652T1 (de) Piperazinderivate als agonisten des melanocortin- rezeptors
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
DE60308996D1 (de) Melanocortinrezeptoragonisten
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
ATE412647T1 (de) Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
PE20170464A1 (es) Terapia de combinacion de alzheimer usando un anticuerpo monoclonal abeta anti-n3pglu mas un inhibidor de bace
PE20142040A1 (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos
EA201201201A1 (ru) Новые ингибиторы rock
ECSP056017A (es) Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2009137251A3 (en) Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
MX2016008079A (es) Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis.
EA200601985A1 (ru) Новые производные индазола и индолона и их применение в качестве фармацевтических средств
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
AR076617A1 (es) Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
DOP2005000095A (es) Nuevos derivados de aminopiridina y su uso como farmacos
DOP2005000093A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
MX2012014968A (es) Dosis fija de una combinacion farmaceutica de tadalafilo y dapoxetina.
EA201792070A1 (ru) Средство для лечения дисфункции лобной доли
TW200509891A (en) Selective serotonin reuptake inhibitors in the treatment of disease